Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial

Olivier Caron; Thierry Frebourg; Patrick R Benusiglio; Stéphanie Foulon; Laurence Brugières

doi:10.1001/jamaoncol.2017.1358

Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial

JAMA Oncol. 2017 Dec 1;3(12):1736-1737. doi: 10.1001/jamaoncol.2017.1358.

Authors

Olivier Caron¹, Thierry Frebourg^{2

3}, Patrick R Benusiglio¹, Stéphanie Foulon^{4

5}, Laurence Brugières⁶

Affiliations

¹ Département de Médecine Oncologique,Gustave Roussy Hôpital Universitaire, Villejuif, France
² Normandie University, INSERM U1245, Rouen, France
³ Department of Genetics, Rouen University Hospital, Rouen, France
⁴ Service de Biostatistique et d’Epidémiologie, Gustave Roussy, Villejuif, France
⁵ CESP Centre for Research in Epidemiology and Population Health, INSERM U1018, Paris-Sud University, Villejuif, France
⁶ Département de Cancérologie de l’enfant et de l’adolescent,Gustave Roussy Hôpital Universitaire, Villejuif, France

Abstract

This interim analysis of an ongoing randomized clinical trial presents preliminary findings regarding use of whole-body magnetic resonance imaging for cancer surveillance of TP53 mutation carriers.

Trial registration: ClinicalTrials.gov NCT01464086.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma of Lung / diagnostic imaging*
Adenocarcinoma of Lung / genetics
Adolescent
Adult
Aged
Child
Female
Germ-Line Mutation*
Humans
Li-Fraumeni Syndrome / diagnostic imaging*
Li-Fraumeni Syndrome / genetics
Lung Neoplasms / diagnostic imaging*
Lung Neoplasms / genetics
Magnetic Resonance Imaging
Male
Middle Aged
Sensitivity and Specificity
Tumor Suppressor Protein p53 / genetics*
Whole Body Imaging
Young Adult

Substances

TP53 protein, human
Tumor Suppressor Protein p53

Associated data

ClinicalTrials.gov/NCT01464086